Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Cyclerion Therapeutics, Inc. | cycn-ex322_7.htm |
| EX-32.1 - EX-32.1 - Cyclerion Therapeutics, Inc. | cycn-ex321_6.htm |
| EX-31.2 - EX-31.2 - Cyclerion Therapeutics, Inc. | cycn-ex312_8.htm |
| EX-31.1 - EX-31.1 - Cyclerion Therapeutics, Inc. | cycn-ex311_9.htm |
| EX-21.1 - EX-21.1 - Cyclerion Therapeutics, Inc. | cycn-ex211_11.htm |
| EX-4.1 - EX-4.1 - Cyclerion Therapeutics, Inc. | cycn-ex41_12.htm |
| 10-K - 10-K - Cyclerion Therapeutics, Inc. | cycn-10k_20201231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
|
|
(1) |
Registration Statement (Form S-3 No. 333-242334) of Cyclerion Therapeutics, Inc. and the related Prospectus, |
|
|
(2) |
Registration Statement (Form S-3 No. 333-240095) of Cyclerion Therapeutics, Inc. and the related Prospectus, and |
|
|
(3) |
Registration Statement (Form S-8 No. 333-230615) pertaining to 2019 Equity Incentive Plan, 2019 Employee Stock Purchase Plan, Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan, and Amended and Restated 2005 Stock Incentive Plan of Cyclerion Therapeutics, Inc.; |
of our report dated February 25, 2021, with respect to the consolidated financial statements of
Cyclerion Therapeutics, Inc included in this Annual Report (Form 10-K) for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Boston, Massachusetts
February 25, 2021